Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.85 +0.68 (+0.75%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

74 75 Next >

AstraZeneca Earnings Preview ↗

July 27, 2023

Via Benzinga

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

July 27, 2023

From AstraZeneca

Via Business Wire

Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports ↗

July 26, 2023

The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss...

Via Benzinga

Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings ↗

July 26, 2023

Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week.

Via Investor's Business Daily

Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility ↗

July 21, 2023

Via Benzinga

Why Pieris Pharmaceuticals Shares Shooting Higher Today? ↗

July 18, 2023

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company

Via Benzinga

NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories ↗

July 18, 2023

Wall Street Journal

Via Benzinga

AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants ↗

July 18, 2023

The FDA approved AstraZeneca Plc (NASDAQ:

Via Benzinga

The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market ↗

July 17, 2023

The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030.

Via Benzinga

This Is What Whales Are Betting On AstraZeneca ↗

July 13, 2023

Via Benzinga

A Look Into AstraZeneca's Debt ↗

July 07, 2023

Via Benzinga

AstraZeneca Unusual Options Activity ↗

July 03, 2023

Via Benzinga

AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment ↗

July 03, 2023

The company tested a treatment in combination with Daiichi Sankyo.

Via Investor's Business Daily

3 Doomed Biotech Stocks Destined for Disaster ↗

July 17, 2023

Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures.

Via InvestorPlace

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly? ↗

July 13, 2023

An overweight world is hungry for new treatments. For now, two companies own the market.

Via Investor's Business Daily

These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts ↗

July 12, 2023

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis ↗

July 11, 2023

One in eight women will be diagnosed with breast cancer during

Via Benzinga

What's Going On With Novavax (NVAX) Stock? ↗

July 10, 2023

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher on Monday after the company announced an amendment to its Canada supply agreement, under which the Government of Canada will pay Novavax $349.6...

Via Benzinga

AstraZeneca Unusual Options Activity For June 28 ↗

June 28, 2023

Via Benzinga

Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review ↗

July 07, 2023

Automakers rallied on sales while Meta's Threads had a big launch.

Via Investor's Business Daily

Biotech Blues: Stay Balanced Through July Earnings Season ↗

July 05, 2023

Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts.

Via Talk Markets

These Were Monday's 2 Stock Movers That Investors Cared About the Most ↗

July 03, 2023

On a quiet day on Wall Street, a couple of stocks still saw a considerable amount of activity.

Via The Motley Fool

AstraZeneca Losses Leave The FTSE In The Red To Start July ↗

July 03, 2023

Despite reaching record highs earlier this year, the UK's FTSE 100 experienced a decline in the April-June period due to volatile commodity prices and persistent inflation concerns.

Via Talk Markets

AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday ↗

July 03, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...

Via Benzinga

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

July 03, 2023

From AstraZeneca

Via Business Wire

AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial ↗

July 03, 2023

AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...

Via Benzinga

4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

July 01, 2023

Bargains abound with the innovation-driven Nasdaq Composite still well below its all-time high.

Via The Motley Fool

AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer ↗

June 29, 2023

AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...

Via Benzinga

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial

June 29, 2023

From AstraZeneca

Via Business Wire

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

June 28, 2023

From AstraZeneca

Via Business Wire

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.